Most drug discovery efforts in amyotrophic lateral sclerosis (ALS) have relied on cell models that represent a narrow slice of the disease. A new collaborative initiative is working to broaden that base.
The ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience launched Patient iPSC-based Research to Improve Sporadic ALS Modelling (PRISM) on March 31, 2026, with the goal of developing and distributing standardized, patient-derived induced pluripotent stem cell (iPSC) motor neuron models for use across the ALS research community.
The problem PRISM targets is well-documented: while roughly 85 percent of ALS cases are sporadic — meaning no identifiable inherited cause — much of the field's preclinical work has depended on gene-edited cell lines or models derived from rare familial subtypes. Those models have often been traced back to a single donor, typically a middle-aged male, which does little to capture the range of biology seen across the actual patient population. That mismatch between the models used in the lab and the patients enrolled in trials is widely considered a contributing factor to the disease's high clinical trial failure rate.
Closing the model gap
The models in PRISM are derived from samples contributed by people living with ALS through ALS TDI's ALS Research Collaborative (ARC) Study, the longest-running longitudinal patient study in ALS, which has enrolled more than 1,800 participants.
Because donors also contributed detailed clinical data, the resulting cell lines are linked to information on age, sex, disease progression, and treatment response — context that gene-edited lines typically lack. Over more than a decade, ALS TDI has built one of the most comprehensive collections of ALS-specific iPSCs available, creating a resource that PRISM is now looking to put to broader use.
Standardization is central to the initiative. Historically, iPSC-derived models have varied considerably across labs depending on the protocols used to grow and mature cells, making it difficult to reproduce or compare results. Without a shared baseline, findings generated in one lab are often difficult to validate in another — a problem that has compounded over time as the field has grown and fragmented across institutions.
PRISM aims to address that by using consistent production methods through Axol's manufacturing infrastructure, then making the cells available for researchers to purchase or request through custom orders. Motor neurons derived from sporadic ALS lines will be added to Axol's existing portfolio, which already includes several iPSC-derived motor neuron cell types from both unaffected donors and patients with familial ALS subtypes.
"By leveraging Axol's scalable manufacturing infrastructure, we will facilitate access to standardized iPSC-derived cells that empower researchers to stratify patients, assess subgroup responses to therapies, and reduce late-stage clinical trial failures," Sapna Vyas, Head of Scientific Programs at Axol Bioscience, told DDN.
For drug developers, models that span a wider range of sporadic ALS biology mean earlier and more meaningful filtering — compounds can be tested across diverse patient subtypes before reaching the clinic, helping to identify which treatments are likely to work for which patients rather than surfacing that information only after a trial has failed. The initiative also aligns with the FDA Modernization Act 3.0, which has expanded acceptance of human-relevant, non-animal approaches in preclinical research — a shift that makes access to well-characterized human cell models increasingly important for teams designing early-stage studies.
"We know that ending ALS will require delivering the right treatments to the right individuals," said Fernando Vieira, CEO and Chief Scientific Officer at ALS TDI, in a press release. "By characterizing iPSC-derived motor neurons from sporadic ALS and making these cells broadly accessible, PRISM ALS will facilitate global drug discovery. This program is only possible thanks to the people living with ALS who contributed samples and data through the ARC Study."
Paul Wright, Head of Motor Neurone Disease (MND) at LifeArc, added that the ambition extends beyond incremental progress. "Our hope is that the stem cell models we produce can unleash a new generation of treatments that could be effective against this disease by slowing its progression and, ultimately, curing it."
